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Abstract
Background: Malaria is the commonest imported infection in the UK. Malaria requiring ICU admission has a
reported mortality of up to 25%. The relationship between ethnicity, immunity, and risk of malaria is complex. The
Malaria Score for Adults (MSA) and Coma Acidosis Malaria (CAM) score have recently been proposed to risk stratify
patients with malaria.
Methods: Retrospective study of patients with WHO severe falciparum malaria admitted to ICU at the Hospital for
Tropical Diseases, London, UK. The relationship between clinical variables and risk of death or a prolonged ICU stay
were examined with logistic regression. The predictive value of the MSA and CAM score were calculated.
Results: 124 patients were included. Cerebral malaria and acute kidney injury occurred earlier (median day 1) than
acute respiratory distress syndrome (median day 3). Six patients had community acquired bacterial co-infection.
Eight patients were co-infected with HIV, five of whom were newly diagnosed. The positive predictive value of a
CAM score ≥2 or an MSA ≥5 for death were 12% and 22% respectively. Five patients died. No variable was
significantly associated with risk of death. There were no significant differences between individuals raised in
endemic countries compared to non-endemic countries.
Conclusions: Mortality in patients managed in a specialist centre was low. Patients who died succumbed to
complications associated with a prolonged stay on ICU rather than malaria per se. The clinical usefulness of the MSA
and CAM score was limited. Co-infection with HIV was relatively common but compared to studies in children,
bacteraemia was uncommon. The relationship between ethnicity and immunity to severe disease is complex.
Background
Approximately 1700 cases of imported malaria are seen
each year in the United Kingdom, of which P. falcip-
arum is both the most common and the most severe [1],
and it remains the most significant imported parasitic
infection in North America, Europe and Australasia
[2-4]. While the number of deaths from imported mal-
aria is low, it has the potential to cause significant mor-
bidity. The case fatality rate for P. falciparum in the UK
is less than 1% but in previous series the mortality rate
for those patients requiring admission to an intensive
care unit (ICU) as a result of malaria has varied from 7%
to 25% [5-11]. Most data on severe malaria come from
endemic countries. Severe imported malaria seen in
non-endemic countries is a very different clinical entity,
particularly in terms of the resources available to care
for critically ill patients, median age at presentation
(mainly children in Africa and young adults in Asian
series) and the likely effect of partial immunity from pre-
vious infection on disease progression in endemic
countries.
Identifying those at high risk of death is important for
subsequent treatment decisions. The Glasgow Coma
Score (GCS) is widely accepted as a tool for identifying
patients most at risk of a poor outcome and cerebral
malaria in a non-endemic setting is usually defined for
practical purposes as a GCS <11. Recently two scoring
systems – Malaria Score in Adults (MSA) [12] and the
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Coma Acidosis Malaria (CAM) Score [13] have been
suggested as additional systems to identify those pa-
tients at higher risk of death. However, neither of these
has previously been validated among patients with
imported malaria.
Earlier reports of severe imported malaria have shown
that cerebral malaria, adult respiratory distress syndrome
(ARDS) and acute kidney injury (AKI) are the most
common complications of malaria requiring admission
to ICU [5-11]. The inclusion criteria for these studies
have varied; some included patients with non-severe
malaria admitted to ICU while others included all pa-
tients with malaria who met at least one of the World
Health Organisation’s (WHO) criteria for severe disease
[14] regardless of whether or not they were admitted to
ICU. Definitions of hyperparasitaemia also varied with
2%, 4% and 5% taken as cut-off values in different pa-
pers. Only two papers [5,6] have included data on the
rates of bacterial co-infection. None of these earlier
studies have included patients treated with Artemisinin-
based therapy and in only one study [11] were exchange
transfusions used. Data on any long term sequelae fol-
lowing severe imported malaria are also scarce.
The concept of immunity to malaria is widely accepted
but poorly understood. In areas of high endemicity, chil-
dren gradually acquire immunity to the disease as a re-
sult of repeated exposure to infection, such that by the
age of approximately five years severe malaria is unlikely
to occur. Should such a child then move away from an
endemic area, this immunity is thought to be lost rela-
tively quickly and, within a matter of months or years,
the child would again be at risk of severe disease. Unfor-
tunately, no laboratory marker of “immunity” to malaria
has been identified. The length of time that an individual
has lived in a malaria-endemic area is often used as a
proxy for immunity. Conversely, people who were born
and raised in parts of the world where malaria transmis-
sion does not occur are widely assumed to be “naïve”
and therefore at higher risk of severe disease. We aimed
to examine whether any previous exposure to malaria
would have an appreciable effect on the manifestations
of severe malaria by stratifying patients according to
their perceived “immunity” [15].
The inter-relationship between malaria and HIV in-
fection has been studied almost exclusively in endemic
areas. Co-infection with malaria has been shown to
have a detrimental effect on HIV viral load and to re-
sult in more frequent and more severe disease [16]. No
data have been reported concerning the prevalence of
HIV infection among patients with severe imported
malaria.
This study therefore set out to examine the main ques-
tions around management of severe malaria in high-
resource non-endemic setting.
Methods
The Hospital for Tropical Diseases (HTD) in London is
part of University College London Hospitals and serves
as a tertiary referral centre for patients with imported
tropical diseases, including malaria. The hospital sees
approximately 75 patients with falciparum each year, of
which about 10% are sufficiently unwell to require ad-
mission to ICU.
Study population
A retrospective study was conducted on all adult pa-
tients (>18 years) seen at HTD/UCLH between 1994
and 2010. During this period a total of 1616 patients
with falciparum malaria were seen, of whom 165 were
sufficiently unwell to require admission to intensive care.
Patients were excluded if they did not meet at least one
of the WHO criteria for severe disease (parasitaemia
>5%, ARDS [bilateral pulmonary infiltrates and PaO2:
FiO2 ratio of <26.7, not attributed to left ventricular dys-
function in the opinion of the ICU clinician], impaired
consciousness [seizures or GCS <11], multiple convul-
sions, shock [systolic BP <80 mmHg despite adequate
filling], abnormal bleeding or coagulopathy [unexplained
clinically significant bleeding or laboratory evidence of
DIC), macroscopic haemoglobinuria, AKI [creatinine >265 -
μmol/L], jaundice [bilirubin >50 μmol/L], hyperlactaemia
[arterial lactate >5 mmol/L], acidosis [pH <7.35 or
serum bicarbonate < 15 mmol/L], hypoglycaemia [blood
glucose <2.2 mmol/L], severe anaemia [haemoglobin
<5 g/dL]) [12]. The diagnosis of malaria was made by
microscopic examination of a blood film. Microscopy
was used to quantify parasitaemia, the presence of
schizonts and co-infections with other forms of Plas-
modia (vivax, ovale, malariae). Most were referred to
HTD from other hospitals where they had already re-
ceived treatment for malaria and, if there was no evi-
dence of asexual parasitaemia at the time of admission
to HTD/UCLH ICU, they were excluded. Of 165 pa-
tients admitted to ICU, 32 had notes which could not be
found, eight no longer had asexual parasites on their
blood film and one did not fulfil any of the WHO cri-
teria for severe disease, leaving a total study population
of 124.
Data collection
Demographic, travel, clinical, laboratory and modalities
of treatment data were collected from clinical notes and
laboratory databases using a standard case report form.
Complications of malaria were defined according to
WHO guidelines on severe malaria [14]. Blood cultures
that were positive within 48 hours of admission were
taken to represent community-acquired infection; posi-
tive cultures after this time were defined as nosocomial.
For the purposes of analyses, patients were classified as
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“malaria-naïve’ if they had been born and raised outside
a malaria-endemic area. Patients who were born in an
endemic area but who had moved away a minimum of
two years earlier were classified as having “little” im-
munity to malaria. Patients who were born and still resi-
dent in an endemic area at the time of admission were
assumed to have “some” immunity to malaria.
Management
All patients were managed according to UK guidelines
[17]. Until 2007, these recommended a loading dose of
quinine (20 mg/kg) given intravenously over 4 hours,
followed by 10 mg/kg until such time as a blood film
was negative for asexual parasites. Exchange transfusion
was considered for patients with a parasitaemia greater
than 20% or those who had a parasitaemia greater than
10% with evidence of end-organ dysfunction. After 2007,
intra-venous artesunate replaced quinine as first-line
treatment for patients with a parasitaemia greater than
10% at HTD, depending on drug availability. All patients
received a second anti-malarial agent, most commonly
sulfadoxine/pyrimethamine. Decisions concerning organ
support and adjunctive therapy were made exclusively
by ICU staff.
Statistical analyses
Continuous variables were described with mean and
standard deviation (SD) or with median and interquartile
range (IQR) as appropriate. Categorical data were de-
scribed with numbers and percent. “Severe ICU malaria”
was defined as death or an ICU stay greater than seven
days. The patients’ MSA and CAM scores on admission
to hospital were calculated as previously described
[12,13]. The relationship between the MSA and CAM
scores and risk of death and severe ICU malaria were
compared using chi-square. Logistic regression was used
to examine variables, including in the model the pres-
ence or absence of complications, age, gender and im-
mune status, to determine factors associated with either
death or severe ICU malaria. All analyses were carried
out using Stata 10 (Statacorp).
Ethics approval
The study was reviewed and approved by the Audit and
Research Committee at HTD who granted ethical ap-
proval for the study and stated that individual patient
consent was not required as this was a retrospective case
note review.
Results
Patient characteristics
Demographic data are shown in Table 1. Most (n = 103,
83%). were transferred to UCLH from another centre.
The median time from initial admission to transfer to
UCLH was 16 hours (IQR 8–30 hours). The largest
group were Caucasian (61, 49%), while 41 (33%) were
African. Very few took antimalarial chemoprophylaxis.
Only one patient claimed to be fully adherent with an
appropriate regimen. Nearly all (116, 94%) acquired their
infection in sub-Saharan Africa. Seven had a clear his-
tory of having received treatment for malaria in the past.
Three were already known to have HIV infection.
Table 1 Demographics
Male 78 (63%)
Age - years – median (IQR) 46 (35–55)
Ethnicity Caucasian 61 (49%)
African 41 (33%)
Other 18 (15%)
Unknown 4 (3%)
Previous malaria exposure Raised outside endemic area 68 (55%)
Born in endemic area + left > 2 years ago 46 (37%)
Born and still resident in endemic area 7 (6%)
Unknown 3 (2%)
Travel to sub-Saharan Africa Chemoprophylaxis 116 (94%)
None 87 (70%)
Inadequate 25 (20%)
Adequate 1(1%)
Unknown 11 (9%)
Reported previous malaria 7 (6%)
Known HIV 3 (3%)
Time from returning to UK and admission - median days (IQR) 9.5 (3–14)
Time from symptom onset to seeking healthcare – median days (IQR) 4 (3–6)
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Median time since returning to the UK was 10 days
(IQR 3–14). Median time from symptom onset to pres-
entation was four days (IQR 3–6).
Sixty-eight (55%) were classified as malaria-naïve.
Forty-six (37%) were assumed to have “little” immunity
to malaria as they had grown up in an endemic area.
Seven were both born and usually resident in a malaria-
endemic area at the time of admission and were as-
sumed to have at least “some” degree of immunity.
Malaria diagnosis
Median parasitaemia at admission, either to UCLH or
the referring hospital, was 6.1% (IQR 2.6 - 18%). Ninety
eight (79%) and 73 (59%) had a parasitaemia greater
than 2% and 5% respectively. One hundred and eight
(87%) and 82 (66%) patients had at least one parasite
count greater than 2% and 5% respectively during admis-
sion. Twenty-two (18%) had schizonts at admission, and
a further 53 (43%) had schizonts at some time during
admission. Four had mixed infections, two with P.
malariae, and one each with P. vivax and P. ovale.
Management
One hundred and twenty three (99%) received intraven-
ous quinine as their initial treatment, 93 (76%) of whom
received a loading dose. Twenty were subsequently
switched to an artemisinin derivative, 18 of whom re-
ceived artesunate. One was treated with an artemisinin
derivative from the start.
Thirty-three (27%), with a median parasitaemia of
25%, had an exchange transfusion performed. Forty six
(37%) required ventilation at some time. Similarly 43
(35%) required renal replacement therapy and 43 (35%)
required inotropic support. Median length of stay in
ICU was 10 days (IQR 7–19) but several had a
prolonged stay, the longest being 90 days.
Complications of malaria
Patients met a median of three (IQR 2–5) WHO criteria
for severe disease (Table 2). 80% of those with cerebral
malaria and 75% of those with AKI developed these
complications within 48 hours and tended to recover
relatively quickly. In contrast, only two patients had
ARDS at admission, while a further 22 developed ARDS
later on, with a median time from admission to diagno-
sis of ARDS of three days (Figure 1). Patients with cere-
bral malaria and / or AKI had a higher parasitaemia at
the time these complications became apparent compared
to those patients who developed ARDS (Figure 2).
More than half (68, 55%) were acidotic at some stage.
Hypoglycaemia (defined as blood glucose <2.2 mmol/L)
was not seen at admission but five patients, all treated
with intravenous quinine, developed this at some point.
Shock occurred in 34 (27%). Significant bleeding or
coagulopathy was less common, occurring in 13 (11%)
patients most of whom had laboratory evidence of DIC.
One patient, who ultimately made a complete recovery,
sustained spontaneous rupture of their spleen. Another
developed purpura fulminans, which necessitated bilat-
eral below-knee amputations.
Co-infections
Six had a community-acquired co-infection; three had clin-
ical and/or radiographic evidence of pneumonia while one
had a coincidental buttock abscess. Two patients had a
positive blood culture at admission, one Staphylococcus
aureus and another Klebsiella pneumoniae. In one other,
Mycobacterium tuberculosis was found in a sputum sample.
Twenty (16%) developed nosocomial infection during
their stay most commonly caused by Staphylococcus aur-
eus (n = 7), Haemophilus influenzae (n = 5) and Pseudo-
monas (n = 2). Sixteen developed pneumonia, two had
proven fungal infection, one bacteraemia with Staphylo-
coccus aureus and one an episode of Clostridium difficile
Table 2 Manifestations of severe disease
Present at admission During admission
Hyperparasitaemia >2% 98 (79%) 108 (87%)
>5% 73 (59%) 82 (66%)
Acidosis pH <7.35 37 (30%) 68 (55%)
AKI: creatinine >265 μmol/L 28 (23%) 55 (44%)
GCS <11 19 (15%) 44 (35%)
Shock: systolic BP <80 mmHg 15 (12%) 34 (27%)
Coagulopathy 7 (6%) 13 (11%)
Seizures 4 (3%) 9 (7%)
ARDS 2 (2%) 24 (19%)
Hypoglycaemia <2.2 mmol/L 0 (0%) 5 (4%)
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colitis. Three patients, all African, were previously known
to have HIV. Of 22 patients who were tested for HIV dur-
ing admission, a further five were found to be positive,
four of whom were African.
Outcomes
One hundred and nineteen (96%) survived and all but
one, the patient who developed purpura fulminans, ul-
timately made a complete recovery. Of the five patients
who died, four were Caucasian; one was an African
woman who had grown up in sub-Saharan Africa but left
two years previously (Table 3). Their median parasit-
aemia was 18% (range 3.2 - 26%) and four had schizonts.
All five were acidotic, all had AKI, three had either
seizures or a GCS < 11 and two developed ARDS. Four
required mechanical ventilation, four required renal re-
placement therapy, three had an exchange transfusion
and in four of the five cases the malaria film was nega-
tive at the time of death. In only one could the cause of
death be directly attributed to malaria, a patient who
died of multi-organ failure on day three when their para-
sitaemia was still more than 2%. One patient died on
day four as a result of cardiac arrhythmias which may
have been precipitated by high-dose inotropes. The other
three patients all died as a result of complications associ-
ated with prolonged ICU stay (disseminated fungal infec-
tion; multi-organ failure; staphylococcal pneumonia).
Twelve had persisting renal impairment at the time of
discharge from ICU, but all of these ultimately recov-
ered. After discharge from hospital, three needed re-
admission, one patient developed an acute confusional
state which was diagnosed as a post malaria neurological
syndrome and the patient made a complete recovery
while two had a relapse of P. falciparum which
responded to a further course of treatment.
There was no demonstrable association between the
amount of “immunity” to malaria (naïve, “little”) and the
risk of severe ICU malaria (69% vs 63%, p = 0.54), cere-
bral malaria (67% vs 65%, p = 0.83), ARDS (78% vs 85%,
p = 0.34) or AKI (61% vs 46%, p = 0.10). In logistic re-
gression adjusting for the potential confounding factors
outlined in the methods, no clinical factor was signifi-
cantly associated with either death or severe ICU
malaria.
A CAM score and an MSA score could be calculated
at admission for 94 (76%) and 124 (100%) respectively.
The positive predictive value of a CAM score <2 and an
MSA score <5 for survival were 100% and 97% respect-
ively. The positive predictive value of a CAM score ≥2
or an MSA ≥5 for death were 12% and 22% respectively.
A CAM score ≥2 was significantly associated with an in-
creased risk of death (12% vs 0%, p = 0.02) and of severe
ICU malaria (50% vs 21%, p = 0.003). An MSA score ≥5
was associated with an increased risk of death (22% vs
3%, p = 0.04) but was not associated with a statistically
significant increased risk of severe ICU malaria (44% vs
33%, p = 0.49).
Discussion
This report shows that patients with severe malaria re-
quiring admission to ICU who are managed at a special-
ist centre have a good outcome, with a mortality rate of
only 4%. Consistent with previous reports, acute kidney
injury, ARDS, and cerebral malaria were the most com-
mon complications. This report demonstrates that
ARDS occurs later and at lower parasitaemia and em-
phasises the need for vigilance even after patients appear
to be responding to treatment. The data reinforce the
Figure 1 Timing of major manifestations of severe malaria.
Cerebral malaria and acute renal failure most commonly occurred
within 48 hours of presentation. ARDS was an uncommon
manifestation of severe infection at presentation; most cases
occurred from the third day of admission on.
Figure 2 Parasitaemia at the time of occurrence of major
complications of malaria. The median parasitaemia at the time
when cerebral malaria and acute kidney injury developed was 3%
compared to 0.5% when patients developed ARDS.
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idea that there is a complex inter-relationship between
ethnicity, “immunity” and the response to malaria. There
were no significant differences between those individuals
who had grown up in an endemic region and those pa-
tients who were malaria-naive. Co-infection with HIV
was common, especially in patients who were African in
origin. Finally, this report adds to the limited number of
series reporting the efficacy and safety of parenteral
artemisinins in severe malaria in a non-endemic setting
[18-20]. The introduction of these agents has been asso-
ciated with a dramatic reduction in the need for ex-
change transfusion.
In this series, the case-fatality rate was 4%. In contrast,
a paper from Kilifi [21] showed that African children
who had evidence of cerebral malaria, acidosis and
severe anaemia had a 35% risk of death. In the
SEAQUAMAT trial [22], among young Asian adults, the
group treated with quinine had a mortality of 22%. In
Africa, most deaths occur within the first 24 hours and
children who survive beyond three days are much less
likely to die. In this series, only one death occurred at a
time when there was evidence of active malarial infec-
tion and the other four resulted from complications as-
sociated with intensive care, such as cardiac arrhythmia
or nosocomial infection. Previous studies have reported
a mortality rate between seven and 25% [5-11]. Recent
data from the Malaria Reference Laboratory have shown
a marked geographical variation in mortality from
imported malaria from different parts of the UK [23]. It
is possible that the lower mortality in various specialist
centres may be a reflection of wider experience in the
management of severe malaria.
Most patients were young, Caucasian travellers to
Africa but the second largest group were Africans visit-
ing friends and relatives. For both groups, adherence to
chemoprophylaxis was poor. The UK Health Protection
Agency have previously reported an increased risk of ac-
quiring malaria in individuals travelling to visit friends
and relatives [1]. Between 1994 and 2010, HTD treated
1451 patients for falciparum malaria who did not require
Table 3 Clinical characteristics of patients who died
Patient
No.
Demographics Travel data Manifestations of severe
malaria
ICU
support
Death
1 31 year old
female
Travelled to Zambia Hyperparasitaemia Exchange Died Day 3
Black African No Chemoprophylaxis Seizures transfusion Parasite Count 2.1%
Raised in
Endemic
ARDS Ventilated
Region AKI RRT
Acidosis Inotropes
2 25 year old male Travelled to Uganda and Hyperparasitaemia Exchange Died Day 19
White Kenya AKI transfusion Disseminated fungal infection
Not-Raised in No Chemoprophylaxis Acidosis RRT
Endemic Region Treatment for malaria
started abroad: Chloroquine then
Quinine
3 83 year old male Travelled to Kenya AKI Exchange Died Day 9
White No Chemoprophylaxis ARDS transfusion Multi-organ failure, shock with
limb
Not-Raised in GCS < 11 Ventilated
Endemic Region Acidosis RRT
Shock Inotropes
Coagulopathy
4 41 year old male Travelled to Gambia Hyperparasitaemia Ventilated Died Day 4
White No Chemoprophylaxis Acidodsis Inotropes VT followed by Cardiac Arrest
Not-Raised in AKI
Endemic Region GCS < 11
5 47 year old male Living in Liberia for 2 Years Hyperparasitaemia Ventilated Died Day 11
White No Chemoprophylaxis AKI RRT Staphylococcal pneumonia
Not-Raised in Acidosis Inotropes
Endemic Region
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admission to ICU. Among all these patients, Africans
were significantly less likely than Caucasians to require
ICU admission (OR: 0.26 95% CI: 0.18-0.38) which is in
keeping with earlier reports [24]. However, among those
who did require intensive care, Africans were no less
sick. There were no differences in the number of WHO
markers of severity between Africans and other ethnici-
ties, suggesting that Africans admitted to ICU had no
appreciable immunity to the disease. These findings
highlight the inherent problems in using ethnicity as a
proxy for “immunity” to malaria.
Cerebral involvement and/or AKI tended to be present
on admission or develop within the first 48 hours. ARDS
tended to develop later, often when there was little or no
evidence of persisting malaria. Those caring for patients
with severe malaria need to be aware that an initial re-
sponse to treatment, manifest by a reduction in parasit-
aemia, does not necessarily mean a successful outcome.
Before the introduction of artesunate, this hospital
recommended a six-unit exchange transfusion for pa-
tients with a parasitaemia greater than 20% or those with
a parasitaemia greater than 10% but with evidence of
end-organ dysfunction. In total, 33 (26%) patients had
an exchange transfusion, including three of the five who
died. Since switching to parenteral artemisinins, we have
seen evidence of a rapid and dramatic decline in parasit-
aemia compared to the response to treatment with quin-
ine. As a result, we have not performed an exchange
transfusion since 2008 and, in agreement with other UK
specialist centres such as the Liverpool School of Trop-
ical Medicine (D Lalloo, personal communication), we
no longer recommend this as a modality of treatment.
Children presenting to African hospitals with malaria
often have positive cultures for gram-negative organ-
isms, particularly non-typhoidal salmonellae. The rate of
blood culture positivity can be as high as 12% [25,26].
Co-existing bacteraemia has been inconsistently reported
in other series of imported malaria, with rates between 2.5
and 5% [5,6]; in this series, only two (1.6%) patients had
positive blood cultures at admission, neither of which
were salmonellae.
The extent of the interaction between HIV and falcip-
arum malaria remains open to debate, but in sub-
Saharan Africa, HIV positive pregnant women in par-
ticular appear to be at an increased risk of developing
severe disease [27]. In this series, three patients were
already known to be living with HIV/AIDS before they
developed malaria; a further five were found to have
HIV during admission, four of whom were African. A
minimum of 17% of Africans therefore were positive for
HIV, which will be an underestimate as not all were
tested. These findings and the shared epidemiological
risk factors for both diseases suggest that all patients
presenting with severe malaria should be tested for HIV.
This study shows that both a CAM score <2 and an
MSA <5 identified patients who would survive. However,
these scores had limited ability to predict mortality and
it remains unclear what role, if any, they may play in
clinical practice in areas of the world where malaria is
not endemic. No clinical factor was associated with a
poor outcome but given the low case fatality rate, the
study was under-powered to detect such a difference.
The main limitation of this study was its retrospective
nature; as a result some data were missing or incom-
plete. Despite this, data capture was high, in particular
data relating to ICU care, which were recorded system-
atically. Although the possibility of referral bias can not
be excluded it is likely that our data are applicable to all
patients with imported malaria requiring admission to
ICU.
Conclusions
This paper suggests that most adult patients with severe
malaria who are managed in a specialist centre survive.
Cerebral malaria and AKI tend to occur early in the dis-
ease, while ARDS develops later. Patients who die tend
to do so because of complications associated with inten-
sive care rather than malaria per se. Africans who have
left an endemic area seem to be at the same risk of se-
vere disease as malaria-naive individuals. The increasing
use of artesunate has been associated with a reduced
need for exchange transfusion, even in patients with very
high parasitaemia. In contrast to children, bacterial co-
infections were uncommon. No single factor consistently
identified individuals at risk of death. Both the MSA and
CAM scores accurately predicted survival in low-risk pa-
tients but had limited power to identify those at high
risk of death. All patients with malaria should be
screened for HIV.
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